Fractures were observed in 2.6% of women taking pioglitazone compared to 1.7% of women treated with a comparator.
Luumurdude esinemist vaadeldi 2, 6% pioglitasooni saanud naistel, võrreldes 1, 7% võrdlusravimit saanud naisega.